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Patatin-like phospholipase
domain-containing protein
3 (PNPLA3)Abstract Hepatitis C virus (HCV) has been associated with high prevalence of steatosis and ﬁbro-
sis. The impact of single-nucleotide polymorphisms (SNP) of patatin-like phospholipase domain-
containing protein 3 (PNPLA3) on the development of steatosis and ﬁbrosis is not clariﬁed for
Egyptian patients with chronic hepatitis C (CHC).
The aim of the study was to assess whether the PNPLA3 I148M variant predisposes to steatosis,
and to progressive liver damage, as evaluated ﬁbrosis stage in Egyptian patients with CHC.
Subjects and methods: 218 CHC Egyptian patients were enrolled in the study, they were grouped
by Ishak stage of ﬁbrosis on liver biopsy into group I (ﬁbrosis score 0 or 1; n 81), group II (ﬁbrosis
score 2 or 3; n 72) and group III (ﬁbrosis score 4–6; n 65). DNA was ampliﬁed by polymerase chain
reaction.
Results: PNPLA3 genotype was not associated with metabolic parameters, including body mass
index (BMI) and lipid levels, but the presence of G allele is associated with higher liver enzymes and
viral loads levels. The PNPLA3 G allele was associated with the severity (stage) of ﬁbrosis
(X2 = 35.83, P= 0.000). Steatosis was detected in 40.7% of C allele carriers and 58.53% of G allele
carriers. The rs738409 G allele was signiﬁcantly associated with steatosis in the overall CHC
patients with different ﬁbrotic stages (X2 = 6.023, P= 0.018) odds ratio (OR) and 95%
CI = 1.99 (1.146–3.47).
Conclusion: Steatosis and ﬁbrosis severity seems to be PNPLA3 I148M regulated, independently
to metabolic parameters but with signiﬁcant association with viral loads and liver enzymes values in
Egyptian patients with CHC.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Ain Shams University. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Chronic hepatitis C infection (CHC) affects more than 170
million individuals worldwide, representing a leading cause
of liver-related mortality [1]. CHC encompasses a wide spec-
trum of diseases, ranging from minimal disease to active hep-
atitis, which frequently progresses to cirrhosis and
hepatocarcinoma [1]. Although approximately 80% of patients
who acquire hepatitis C virus (HCV) infection will develop a
chronic low grade slowly progressive hepatitis, perhaps only
20–30% of infected patients will progress to clinically signiﬁ-
cant ﬁbrotic disease after 20–30 years [2]. Hepatic stellate cells
(HSC) are thought to play a pivotal role in ﬁbrogenesis within
the liver [2]. Steatosis accelerates activities and progression of
chronic hepatitis C and is independently associated with stage
III/IV hepatic ﬁbrosis [3]. Overall sustained virological
response to treatment in HCV-infected patients with steatosis
is also considerably lower than in those without steatosis [4].
Patatin-like phospholipase domain-containing 3 (PNPLA3)
gene, also called adiponutrin, with a molecular mass of
approximately 53 kDa that in humans is mainly expressed in
intracellular membrane fractions in hepatocytes [5,6] which
encodes a 481 amino acid protein, is a triacylglycerol lipase
conserved from potatoes to humans with 10-fold higher
expression in liver compared to adipose tissue [5]. Variation
in PNPLA3 gene contributes to ethnic and inter-individual dif-
ferences in hepatic fat content and susceptibility to nonalco-
holic fatty liver disease (NAFLD) [6]. It was reported that
the minor allele of rs738409 C/G, a nonsynonymous coding
single nucleotide polymorphism (SNP) in the PNPLA3 gene
encoding I148M change, was associated with steatosis, portal
inﬂammation, lobular inﬂammation, Mallory-Denk bodies,
NAFLD activity score (NAS) and ﬁbrosis [7]. Minor allele
of rs738409 C/G is also strongly associated with hepatic fat
content and with elevated serum levels of ALT and AST [8].
Toll-like receptor 4 (TLR4) is a receptor for bacterial
lipopolysaccharide (LPS), which is suggested to be involved
in the pathogenesis of hepatobiliary diseases [9]. There is
accumulating evidence that LPS and TLR4 play a key role
in the pathogenesis of HCV infection. Patients with chronic
HCV infection display increased serum levels of LPS even in
the absence of signiﬁcant hepatic ﬁbrosis [10].
The mechanism whereby rs738409 inﬂuences liver fat is
independent of body composition and insulin resistance
[11,12], but likely involves a decreased ability of the 148M
PNPLA3 variant to regulate hepatic lipid metabolism [13].
However, it is not known whether the rs738409 SNP inﬂuences
the steatogenic effect of HCV and the progression of CHC in
Egyptian patients. Although most lines of evidence support a
strong association between steatosis and ﬁbrosis severity in
CHC [14], doubts have been molded as to whether steatosis
is the causative factor driving accelerated hepatic ﬁbrogenesis,
or rather is a simple marker associated with increased fat
stores which would represent the occurrence of underlying dis-
ease progression [15]. This study was designed to assess
whether the PNPLA3 I148M variant predisposes to steatosis,
and to progressive liver damage, as evaluated ﬁbrosis stage
in Egyptian patients with CHC. To explore the possible clinical
relevance of these ﬁndings, we also assessed the effect of
PNPLA3 genotype on metabolic parameters such as lipid
levels, viral load values and liver enzymes in CHC.2. Subjects and methods
This study was carried out in the Medical Biochemistry and
Molecular Biology and Internal Medicine, Pathology
Departments, Faculty of Medicine, Outpatients Clinics,
Intensive Care Unit of Zagazig University Hospitals and
Private outpatient Clinics, Zagazig City during the period from
Nov 2013 to April 2015. In this study we examined the effect
and relationship of allelic variants of the PNPLA3 rs738409
C > G gene in Egyptian patients with chronic HCV infection
with steatosis and different degree of liver ﬁbrosis according to
Ishak classiﬁcation [16]. PCR technique with restriction frag-
ment length polymorphism (RFLP) was used to detect the
gene polymorphism.
2.1. Study subjects
Two hundred and eighteen of chronic HCV infection subjects
(113 females, 105 males) were included in this study. They did
not receive any treatment of hepatitis C virus before the study.
They were diagnosed by clinical, laboratory and ultrasonogra-
phy as HCV infected patients. HCV infection was diagnosed as
+ve enzyme linked immunosorbent assay technique (ELISA)
for anti HCV antibodies. The presence of anti-HCV antibodies
was determined in serum samples by ELISA. Moreover, the
HCV infection was detected by +ve PCR for HCV-RNA
tested by reverse transcription polymerase chain reaction
(RT-PCR) performed on patient sera using Amplicor (Roche
Diagnostics, Lewes, UK). All liver biopsy specimens were
taken under guided ultrasonography, tissue sections were
stained with hematoxylin and eosin, impregnated with silver
for reticulin framework, and stained with trichrome for colla-
gen. They were graded for the degree of necro-inﬂammatory
activity and staged for the extent of ﬁbrosis according to the
criteria of Ishak classiﬁcation [16]. The degree of steatosis
was graded as follows on the basis of the percentage of hepa-
tocytes containing macrovesicular fat droplets: grade 0, no
steatosis; grade 1, <33% hepatocytes containing macrovesicu-
lar fat droplets; grade 2, 33–66% of hepatocytes containing
macrovesicular fat droplets; grade 3, >66% of hepatocytes
containing macrovesicular fat droplets.
Diagnosis of steatosis by Ultrasonography was based on
evidence of ultrasonographic contrast between the hepatic
and right renal parenchyma of the right intercostal sonogram
in the midaxillary line, or abnormally intense, high-level echoes
arising from the hepatic parenchyma, and was graded accord-
ing to intensity on a three-grade scale as none, mild, or severe
[17]. History of risk factors for HCV infection and alcohol
consumption were established. Duration of infection at the
time of liver biopsy was also recorded.
The study was approved by Zagazig University Ethics
Committee, the work has been carried out in accordance with
the code of ethics of the world medical association
(Declaration of Helsinki) for experiments in humans.
Exclusion criteria were positive hepatitis B viral markers, his-
tory of alcohol use, diagnosis of autoimmune hepatitis (a
non-resolving inﬂammation of the liver of unknown cause,
characterized by the presence of interface hepatitis on histo-
logic examination, hypergammaglobulinemia, and autoanti-
bodies) [18]. Liver disease associated with drug use and
primary biliary cirrhosis that can be diagnosed by symptoms
Table 1 Basic characteristics of all participant groups.
Parameters Group I (n= 81) Group II (n= 72) Group III (n= 65) Anova (F) value with P values
Age (years) 48.16 ± 4.67 47.50 ± 4.77 49.34 ± 5.87 F= 1.851, P= 0.104
BMI (kg/m2) 24.95 ± 4.28 25.75 ± 4.91 26.41 ± 4.61 F= 2.18/, P= 0.134
TC (mg/dl) 217.29 ± 34.24 226.28 ± 20.1 218.96 ± 20.53 F= 4.13,P= 0.105
TG (mg/dl) 154.6 ± 21.3 153.4 ± 24.0 160.89 ± 25.12 F= 3.43, P= 0.101
Serum ALT (IU/L) 93.17 ± 23.44 178.61 ± 43.63 193.57 ± 27.25 F= 210.315, P= 0.000*
Serum AST (IU/L) 118.57 ± 43.24 174.88 ± 44.3 175.42 ± 48.65 F= 39.750, P= 0.000*
Serum GGT (IU/L) 73.41 ± 20.19 109.48 ± 14.02 118.94 ± 11.55 F= 169.196, P= 0.000*
Viral load Eq/ml 1 · 106 ± 3.66 · 105 229.96 · 103 ± 143 · 103 854.08 · 103 ± 473.41 · 103 F= 152.270, P= 0.000*
Serum creatinine (mg/dl) 0.97 ± 0.25 0.99 ± 0.24 1.01 ± 0.21 F= 0.41, P= 0.664
Serum urea (mg/dl) 38.18 ± 5.63 39.9 ± 4.78 38.25 ± 6.11 F= 2.47, P= 0.087
N.B. P* signs for signiﬁcant P value.
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mouth and jaundice or can be diagnosed by laboratory ﬁnd-
ings as anti-mitochondrial antibody (AMA) blood test [18].
Patients lacked a liver biopsy, the histological sample was
not adequate, or had coexistent liver diseases were excluded
from the study, Informed consent was obtained from all
patients before participation in this study. The clinical features
of the subjects are summarized in Table 1.
2.2. Sample collection
Ten milliliters fasting venous blood samples were collected
from the subjects using standardized protocol and equipment,
separated into two samples one whole blood for DNA extrac-
tion and PNPLA3 rs738409 gene polymorphism determination
and the other serum sample for estimation of triglyceride (TG),
total cholesterol (TC), urea, creatinine, other liver function test
(LFT) parameters (ALT, AST, GGT) and viral load. They
were measured by standard chemical and enzymatic commer-
cial methods in the Medical Biochemistry Department,
Zagazig University.
2.3. Methods
All subjects are submitted to the following:
(1) Full medical history taking and complete clinical
examination.
(2) Abdominal ultrasonography examination with evalua-
tion of different hepatobiliary parameters including por-
tal, hepatic and mesenteric vein diameters.
(3) Liver biopsy for patients with chronic HCV infection.
(4) Laboratory investigations including:
(A) Routine investigations:– Triglyceride (TG) and total cholesterol (TC)
were estimated by enzymatic method [19].
– Measurement of serum urea and creatinine s-
tandard chemical and enzymatic commercial
methods.
– Anthropometric examination (height and
weight) for calculation of the BMI was done
for all the subjects (kg/m2).
– Liver function tests:
– Serum alanine transaminase (ALT), aspartate
transaminase (AST) and gamma glutamyl
transferase (GGT) using bio-Merieux kit [20].– Viral hepatitis markers: HCV antibodies by
ELISA, HCV RNA–RT-PCR and HBs Ag a-
nd another hepatotropic virus (A).
– Hepatitis biopsy specimen should contain four
pieces of information to most completely assess
the specimen and serve patient care [16]:
(1) The statement that it is, indeed, presence of
chronic hepatitis.
(2) The grade of activity (including the name
of the scoring system used).
(3) The stage of activity (including the name of
the scoring system used).
(4) The known or suspected cause of the
hepatitis.
(5) Hepatitis related changes (hepatitis C-
related fat, increased iron uptake, large cell
and small cell changes) and particularly
common concomitant diseases, such as
alcoholic and nonalcoholic fatty liver dis-
ease and hemochromatosis.2.4. DNA preparation and SNP genotyping
The rs738409 C > G SNP, encoding I148M, was genotyped by
the polymerase chain reaction–restriction fragment length
polymorphism (PCR-RFLP) method according to Islek et al.
[21].
Genomic DNA to be used in molecular analysis was iso-
lated and prepared from leucocytes using Biospin Blood
Genomic DNA Mini-prep Kit (Sigma, Aldrich Co. LLC,
NA2000). The PCR was performed in a Perkin Elmer 4800
thermal cycler (PTC-100 machine, Inc., Watertown, Mass.
USA). PCR was performed with PCR GTX press Master
Mix (Applied Biosystems) as following: 25 lL of PCR master
mix was dispensed into each PCR tube, and then the following
materials were added to each tube containing 100 ng of
extracted DNA, 25 lM forward primer (50-CCCTGCTCACT
TGGAGAAAG-30), and 25 lM reverse primer (50 – TGTCA
CCGGAATAGGGAGGA-30) (Operon Biotechnologies,
Inc.), and then 19 lL dd H2O was added giving a ﬁnal volume
of 50 lL.
The PCR cycling conditions for the rs738409 variant were
as follows: brieﬂy, the genomic DNA was denatured at 95 C
for 5 min, followed by 35 cycles at 95 C for 1 min, 58 C for
30 s, 72 C for 1 min, and a ﬁnal extension step at 72 C for
336 A.M.H. Mackawy et al.10 min. The digestion of the ampliﬁed 139 bp fragment with
the restriction endonuclease NlaIII site at the position of
44324727 bp was carried out at 37 C overnight. The digested
PCR products were resolved on 3% agarose gels stained with
ethidium bromide. PCR method resulted in a 139 bp product
of CC genotype and the GG genotype showed two fragments
of 112 and 27 bp. In heterozygous genotype samples (G/C)
showed three fragments of 139, 112, and 27 bp.3. Statistical analysis
Results were statistically analyzed using SPSS version 16 for
Windows. The statistical data were calculated for mean and
standard deviation (S.D). Analysis of variance (ANOVA)
was used to compare the results of all examined subjects in
all studied groups within group comparisons. Post Hoc
Tukey HSD (high signiﬁcance difference) calculates a new crit-
ical value that can be used to evaluate whether differences
between any two pairs of means are signiﬁcant. Odds ratio
(OR) and 95% conﬁdence interval (CI) for the presence of
HCV infection and steatosis with different liver ﬁbrosis grades
within the PNLP genotypes were analyzed by using the chi
square X2 test. Results were considered signiﬁcant when
P< 0.05.4. Results
Two hundred eighteen chronic HCV infected patients (113
females, 105 males with mean ages of 46.44 ± 6.06 years were
evaluated in this study. Anova test (F-test) revealed a non-
signiﬁcant difference between groups regarding sex and age
(F= 0.976, P= 0.104), ANOVA test (F-test) of different mea-
sured parameters, Table 1.Table 2 Genotype and Allele frequency for PNPLA3
rs738409 gene polymorphism in all studied groups.
C/G
Genotype Groups
Group I
(N= 81)
Group II
(N= 72)
Group III
(N= 65)
N (%) N (%) N (%)
CC 58 (71.6%) 31 (43.1%) 14 (21.53%)
CG 14 (17.28%) 28 (38.8%) 23 (35.38%)
GG 9 (11.11%) 13 (18.1%) 28 (43.1%)
X2// P
value
7.02a// P= 0.03a,*
37.532b// P= 0. 000b *
12.07c// P value = 0.002c *
n (%) n (%) n (%)
C allele 130 (80.25%) 90 (62.5%) 51 (39.20%)
G allele 32 (19.75%) 54 (37.5%) 79 (60.80%)
X2 11.883a 51.493b 30.46c
P 0.001a,* 0.000b,* 0.000c,*
OR 95%CI 2.43 (1.45–4.07) 6.29 (3.73–10.61) 4.35 (2.55–7.44)
Comparison of Group I and Group IIa, Group I and Group IIIb,
Group II and Group IIIc, P* points for signiﬁcant P value.4.1. Fibrosis scores
Ishak classiﬁcation classiﬁed the patients according to the
stage of liver ﬁbrosis on liver biopsy into three groups as
follows:
– Group I: ‘‘HCV with ﬁbrosis score 0 or 1’’: This group com-
prised 81 patients (37.15%) (44 females and 37 males) with
ages ranging between 36 and 56 years with a mean
value ± S.D of 48.16 ± 4.67 years. Steatosis was detected
in 30 patients (37.03%).
– Group II: ‘‘HCV with ﬁbrosis score 2 or 3’’: 72 patients
(33.02%) (40 females and 32 males) were included with ages
ranged from 38 to 57 years with a mean value ± S.D of
47.5 ± 4.77 years. 44 patients (61.11%) had steatosis.
– Group III: ‘‘HCV with ﬁbrosis score 4 or 6’’: 65 patients
(29.81%) (29 females and 36 males) with ages ranging
between 36 and 61 years with a mean value ± S.D of
49.34 ± 5.9 years. Steatosis was reported in 37 patients
(56.92%).
There was no statistical difference between all groups
regarding age and sex (P> 0.05).4.2. Distribution of PNPLA3 gene polymorphism in all patient
groups
The frequency of PNPLA3 rs738409 genotypes is summarized
in Table 2 and Fig. 2. The frequency of C and G allele in total
patients with chronic HCV infection was 271(62.15%) and 165
(37.85%), respectively.
– In group I: The homozygous CC was detected in 58 patients
(71.6%), the heterozygous CG in 14 patients (17.28%) and
the homozygous GG in 9 patients (11.11%). The C and G
allele frequency were 80.25% and 19.75%, respectively.
– In group II: There were 31 patients (43.1%) of homozygous
CC genotype and there were 28 patients with CG genotype
(38.8%), we found only 13 (18.1%) patients carrying the
homozygous GG genotype. The C and G allele frequency
were 62.5% and 37.5%, respectively.
– In group III: The PNPLA3 homozygous CC, heterozygous
CG and homozygous GG genotypes were detected in 14
patients (21.54%), 23 patients (35.38%) and 28 patients
(43.1%), respectively. The C and G allele frequency were
39.2% and 60.8%, respectively.
We revealed a signiﬁcant association with PNPLA3 gene
(C/G) polymorphism among chronic HCV infected patients
with different ﬁbrosis degrees (X2 = 35.83, P= 0.000)
(Table 2).
The GG genotype and the G allele for the PNPLA3
rs738409 were signiﬁcantly more frequent in group III than
in group II and group I patients (X2 = 12.074, P= 0.002
and X2 = 37.532, P= 0.000), (X2 = 30.46, X2 = 51.49,
P= 0.000), odds ratio (OR) and 95% CI for the G
allele = 4.35 (2.55–7.44) and 6.3 (3.73–10.61), respectively.
Moreover, a signiﬁcant increase of GG genotype and G allele
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Figure 1 Frequency of different PNPLA3 genotypes in all
studied groups.
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(X2 = 7.02, P= 0.03, X2 = 11.88, P = 0.001) odds ratio (OR)
and 95% CI for the G allele = 2.43 (1.46–4.07) (see Fig. 1).
4.3. Association between rs738409 genotypes and hepatic ﬁbrosis
stage with or without hepatic steatosis
We investigated the association between rs738409 genotypes
with hepatic ﬁbrosis stage and the presence or absence of hep-
atic steatosis. The results of the analysis revealed an additive
increase in the ﬁbrosis severity and occurrence of steatosis in
the rs738409 G-allele harboring patients. The prevalence ofC G C 
GroupI Grou
41
24
10
6 
19
26
N
um
be
r o
f p
a
en
ts
 
PNPLA3 Gene
Figure 2 Number of HCV patients with and without steatosis accord
columns for the patients without steatosis and the dotted ones for the
Table 3 Number of HCV patients with and without steatosis accor
Patients Group I (N= 81) Group II
C allele N= 65 G allele N= 16 C allele N
Without steatosis 41 (63%) 10 (62.5%) 19 (42%)
With steatosis 24 (37%) 6 (37.5%) 26 (58%)
X2 and P value X2 = 13.17, P= 0.003a *
X2 = 29.92, P= 0. 000b *
X2 = 8.76, P= 0.033c *
Comparison of Group I and Group IIa, Group I and Group IIIb, Groupsteatosis according to rs738409 gene C and G alleles is shown
in Fig. 2 and Table 3. Steatosis was detected in 37.5% and
37% of group I G allele and C allele carriers, respectively. In
group II, 67% of G allele carriers and 58% of C allele carriers
were recorded to have steatosis, while steatosis was proved in
60% of G allele carriers and 52% of C allele carriers in group
III patients. The results showed that presence of steatosis was
signiﬁcantly increased in the G allele carriers relative to the C
allele carriers in all groups (X2 = 34.746, P= 0.000), Table 3.
In overall studied patients, steatosis was detected in 55
patients out of 135 patients of C allele carriers (40.7%) and
48 patients out of 82 patients of G allele carriers (58.53%).
The rs738409 G allele was signiﬁcantly associated with steato-
sis in the overall CHC patients with different ﬁbrotic stage
(X2 = 6.023, P= 0.018) odds ratio (OR) and 95% CI for
the G allele = 1.99 (1.146–3.47). The PNPLA3 rs738409 geno-
type was signiﬁcantly associated with Ishak ﬁbrosis stage,
Homozygosity for the rs738409 G allele was signiﬁcantly more
represented in CHC patients with than in those without steato-
sis, and the association was independent of age, sex, BMI and
lipid levels.
4.4. Data of liver function test (LFT) and other metabolic
parameters (Table 1)
On comparing ALT, AST and GGT serum levels among CHC
patients groups, there was a signiﬁcant increase in group II and
group III than group I patients (Tukey HSD= 85.44, 100.39,
56.311,56.84, 36,07, 45.52, P= 0.000), respectively. ALT andG C G 
pII GroupIII
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ing to PNPLA3 alleles (C and G) for each group. (N.B. Plain solid
patients with steatosis).
ding to PNPLA3 alleles (C and G) for each group.
(N= 72) Group III (N= 65)
= 45 G allele N= 27 C allele N= 25 G allele N= 40
9 (33%) 12 (48%) 16 (40%)
18 (67%) 13 (52%) 24 (60%)
II and Group IIIc, P* points for signiﬁcant P value.
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338 A.M.H. Mackawy et al.GGT showed signiﬁcant increase in group III more than group
I and II patients (Tukey HSD= 14.95, P= 0.02) (Tukey
HSD= 9.45, P= 0.002), respectively, with non-signiﬁcant
association in AST serum between group II and III patients
(Tukey HSD= 0.53, P= 0.997). Viral load values recorded
a signiﬁcant increase in group III and group II patients more
when compared to group I with signiﬁcant increase in
subgroup III more than subgroup II patients (Tukey
HSD= 7.45, 1.3 (P= 0.01) and 6.24, P = 0.000),
respectively.
4.5. Association of PNPLA3 gene genotype with liver enzymes
and other metabolic parameters
In addition, we also compared the PNPLA3 rs738409 geno-
types with different clinical parameters of all studied patients.
In CHC patients the PNPLA3 rs738409 genotype was not sig-
niﬁcantly associated with age, sex distribution, BMI, total
cholesterol (TC) and TG. Otherwise, serum AST, ALT and
GGT levels were signiﬁcantly higher in patients harboring
the G allele. Viral load values (Eq/ml) recorded signiﬁcant dif-
ferences among different PNPLA3 rs738409 genotypes of all
CHC patients to be increased in patients harboring the GG
and G allele, listed in Table 4.
5. Discussion
Since the discovery of hepatitis C, there have been several
investigations of the role of histological biopsy in determining
the severity of chronic hepatitis and progression of disease [22].
Most of these studies used histological scoring systems for
chronic hepatitis that did not include the assessment of steato-
sis [23]. The extent of ﬁbrosis and architectural disturbance
(stage of disease) increases with time, but at a rate that varies
widely between individuals, with some progressing to cirrhosis
within 10 years of viral acquisition, and others showing only
mild ﬁbrosis after 30 years [24]. Steatosis is seen in 30–70%
of liver biopsies from patients with chronic hepatitis C
[25,26], more frequently than is seen in other causes of chronic
hepatitis [27], and in a high proportion of patients no other
cause of fatty liver, such as high alcohol intake or high BMI
can be identiﬁed [28]. Steatosis is thought to be a speciﬁc cyto-
pathic effect of the hepatitis C virus (HCV) and favors hepati-
tis C virus (HCV) life-cycle [29], and may be particularly
associated with the type 3 genotype [30].
Despite being initial hypothesis-driven, case-control studies
identiﬁed some genetic loci associated with the progression of
liver damage, the genetic determinants of NAFLD remained
obscure until recently [31]. By 2008, the ﬁrst genome wide asso-
ciation studies in the ﬁeld of hepatic steatosis allowed to iden-
tify the rs738409 variant, by a hypothesis free drive approach,
as the single major genetic determinant of hepatic fat content.
This sequence variation is a C > G single nucleotide change,
encoding for the 148 Isoleucine to Methionine protein variant
(I148M) of Patatin-like phospholipase domain-containing 3
(PNPLA3) [6].
To our knowledge, there are few studies which discussed
the inﬂuence of rs738409 PNPLA3 SNP, on the risk of patho-
genesis of steatosis and ﬁbrosis progression in CHC Egyptian
patients. Thus, our study was designed to examine the role of
rs738409 C/G genotypes on histologically assessed liver
Patatin-like phospholipase domain containing-3 gene (PNPLA3) I148M polymorphism 339steatosis and the severity of liver ﬁbrosis and to explore the
possible clinical relevance of these ﬁndings, we also assessed
the effect of PNPLA3 genotype on metabolic parameters such
as lipid proﬁle and BMI, viral loads and liver enzymes in CHC.
We evaluated 218 of Egyptian CHC patients, the patients
were classiﬁed according to ﬁbrosis stage by Ishak classiﬁca-
tions into three groups as 37.15% (Ishak = 0–1), 33.02%
(Ishak = 2–3) and 29.81% (Ishak = 4–6). Steatosis has been
detected in group I, group II and group III as follows
37.03%, 61.11% and 56.92%, respectively. We recorded posi-
tive association between occurrence of steatosis and the stage
of ﬁbrosis in HCV patients.
The presence of steatosis in patients with hepatitis C is
dependant on a complex interaction of viral and host related
factors [29]. Steatosis in patients without hepatitis C is related
to alcohol consumption, obesity, high BMI, type II diabetes,
and hyperlipidaemia [32]. These factors are also important in
patients with hepatitis C, but a proportion of patients with
hepatitis C have no other risk factor for steatosis. In particu-
lar, this has been reported to be a feature of genotype 3 infec-
tion, so that patients with moderate to severe steatosis without
other risk factors are probably infected with genotype 3 [28].
This interacts with factors predisposing to steatosis in the host,
particularly high BMI, to result in the expression of steatosis in
a proportion of HCV positive patients [33]. An evidence that
weight reduction in patients who are mildly overweight results
is improvement in steatosis, and in some also in the degree of
ﬁbrosis [33], suggests both the reversibility of steatosis in
patients with chronic hepatitis C, and also the direct impor-
tance of steatosis in the development of ﬁbrosis.
Nishina et al. [34] observed fat accumulation in the liver in
transgenic mice expressing HCV polyprotein and reported that
iron-induced unfolded protein response appeared to be one of
the mechanisms responsible for hepatic steatosis in HCV infec-
tion. HCV particles were observed in close proximity to lipid
droplets, an organelle used for the storage of neutral lipids that
moves dynamically through the cytoplasm, interacting with
other organelles, including the endoplasmic reticulum [35].
These ﬁndings indicate that some steps of HCV assembly take
place around lipid droplets [35], suggesting that this might be a
possible mechanism for HCV directly inducing hepatic
steatosis.
PNPLA3 rs738409 SNP has been previously reported to
inﬂuence liver fat without affecting body composition and
insulin resistance and has been concluded that this genetic vari-
ant affects steatosis development and ﬁbrosis stage in CHC
patients [36,37].
We evaluated the rs738409 PNPLA3 SNP In CHC
Egyptian patients, and observed that this genetic variant of
PNPLA3 gene (C/G) polymorphism affects steatosis develop-
ment and is independently associated with ﬁbrosis severity
among chronic HCV infected patients with different ﬁbrosis
degrees. In line with the prediction that, if steatosis causes
ﬁbrosis progression in CHC, then the rs738409 SNP C/G alle-
les should also be associated with advanced ﬁbrosis. In the pre-
sent study, steatosis has been detected in 37% of G allele
carriers and 36.9% of C allele carriers in group I patients. In
group II, 66.66% of G allele carriers and 57.77% of C allele
carriers were recorded to have steatosis, while steatosis was
proved in 60% of G allele carriers and 52% of C allele carriers
in group III patients. Steatosis was detected in 55 patients out
of 135 patients of C allele carriers (40.7%) and 48 patients outof 82 patients of G allele carriers (58.53%) in overall CHC
patients. The rs738409 G allele was signiﬁcantly associated
with steatosis in the overall CHC patients with different ﬁbro-
tic stages.
Moreover, the association between rs738409 genotype and
steatosis and ﬁbrosis was independent of known risk factors,
such as age, sex, BMI, TC and TG, but we observed a signif-
icant association with liver enzymes such as ALT, AST and
GGT levels and viral loads. Homozygosity for the minor
rs738409 G allele conferred the strongest risk of steatosis
and ﬁbrosis severity.
Our results were in harmony with Valenti et al. [38] and
Romeo et al. [6] who reported that homozygosity for
the minor rs738409 G allele conferred the strongest risk of
steatosis.
Valenti et al. [36] speculated that when steatosis inducing
stressors such as obesity and insulin resistance, excess alcohol
intake, and HCV infection stress the liver, in the presence of
the ‘‘normal’’ 148I PNPLA3 allele the damage will result in
simple uncomplicated steatosis, whereas the 148M ‘‘at risk’’
allele will favor steatohepatitis and ﬁbrogenesis, with progres-
sion toward cirrhosis and its complication in susceptible
individuals.
These ﬁndings were in concordance also with Dongiovanni
et al. [39], Ampuero et al. [40] and Amit et al. [41] who stated
that PNPLA3 allele-G modulated the development of steato-
sis, particularly in patients with HCV.
Association of rs738409 with ALT and AST levels is con-
troversial. In Argentinians with NAFLD [42], Italian adults
with NAFLD [25], obese Italian adults [38], and obese
Italian children [43], the G-allele of rs738409 was found to
be signiﬁcantly related to increased ALT levels. In Finnish
individuals [44], obese Italian adults, the G-allele of rs738409
is signiﬁcantly associated with increased AST levels [39].
However, in the African American, European American [6],
and German [37] populations, rs738409 is not associated with
either ALT or AST levels.
Hotta et al. [45] found that in the Japanese population, the
PNPLA3 rs738409 was associated with plasma levels of ALT,
AST, and the histological ﬁbrosis stage. They suggested that
PNPLA3 may be involved in the progression of ﬁbrosis.
Valenti et al. [15] stated that PNPLA3 genotype inﬂuences
steatosis development in CHC, is independently associated
with cirrhosis and other steatosis-related clinical outcomes,
such as lack of response to antiviral treatment and HCC.
Kitamoto et al. [46] demonstrated that the PNPLA3 gene is
strongly associated with the progression of nonalcoholic
steatohepatitis (NASH) in Japanese, whose BMI is lower than
that of the United States and European countries [47].
It was reported that the minor allele of rs4986791 C
1196C > T, a non-synonymous coding SNP in the Toll like
receptor 4 (TLR4) gene encoding T399I change, emerged as
conferring protection against ﬁbrosis progression compared
to a major, wild-type (WT) CC allele, along with another
highly consegregated SNP (rs4986790, C 896A > G) located
at codon position 299 (p.D299G) [48]. These TLR4 SNPs are
associated with protection against hepatic ﬁbrosis, reduce
TLR4-mediated inﬂammatory and ﬁbrogenic signaling, and
lower the apoptotic threshold of activated hepatic stellate cells
[49] TLR4 SNPs also modulate the risk of liver ﬁbrosis in
Caucasians with chronic hepatitis C infection [50]. This genetic
variant not only inﬂuences the overall amount of
340 A.M.H. Mackawy et al.hepatocellular fat, but by impacting on the concentration or
subcellular localization of speciﬁc lipid species directly modu-
lates inﬂammation. It should not be forgotten that several
lipids behave as inﬂammatory mediators acting through speci-
ﬁc receptors [51]. Alternatively, if the 148M mutation slows
down triglycerides kinetics between cell compartments, it could
be speculated that renders them more susceptible to lipoperox-
idation, leading to oxidative stress, and in turn to hepatocellu-
lar damage and inﬂammation [51].
In conclusion, our results showed association between
PNPLA3 rs738409 and hepatic steatosis and liver ﬁbrosis
severity independently to lipid proﬁle and BMI with signiﬁcant
association with viral loads and liver enzymes, steatosis and
ﬁbrosis severity seems to be PNPLA3 regulated in Egyptian
patients with CHC.
It is possible that the different evaluation methods, such as
Ultrasound and liver biopsy, and different distribution of
PNPLA3 rs738409 genotypes might have different association
with hepatic steatosis and liver ﬁbrosis in Egyptian patients
with chronic hepatitis C. We claim that our study might not
be considered ideal to assess the inﬂuence of rs738409 geno-
type on progression of steatosis and ﬁbrosis in HCV. We also
could not completely rule out the possibility that there exist
different mechanisms of hepatic steatosis and liver ﬁbrosis
and hepatitis C. Actually the different therapeutic regimens
and HCV genotypes, coupled with the fact that the study
was limited to patients who had undergone a liver biopsy,
might have accounted for the this study limitations which calls
for external validation of our data. Moreover, we conducted
this study on a selected group of Egyptian patients and there-
fore it is not known whether these ﬁndings also apply to indi-
viduals in the general community with CHC and to patients of
different ethnicity. Thus, clariﬁcation of the pathogenesis of
liver damage progression in CHC, the association between
PNPLA3 rs738409 GG genotype and steatosis-related clinical
outcomes might identify a subgroup of CHC patients with an
adverse prognosis. Whether evaluation of rs738409 genotype
can help for treatment and follow-up of CHC patients should
be assessed in prospective further studies.Conﬂict of interest
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